More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity.
Neutrophil to lymphocyte ratio (NLR) and standard uptake value (SUV) by 18F-FDG PET represent host immunity and tumor metabolic activity, respectively. We investigated NLR and maximum SUV (SUVmax) as prognostic markers in metastatic pancreatic cancer (MPC) patients who receive palliative chemotherap...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4699704?pdf=render |
id |
doaj-6686868afaec484da9206c1349f02f60 |
---|---|
record_format |
Article |
spelling |
doaj-6686868afaec484da9206c1349f02f602020-11-25T02:31:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01111e014569210.1371/journal.pone.0145692More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity.Younak ChoiDo-Youn OhHyunkyung ParkTae-Yong KimKyung-Hun LeeSae-Won HanSeock-Ah ImTae-You KimYung-Jue BangNeutrophil to lymphocyte ratio (NLR) and standard uptake value (SUV) by 18F-FDG PET represent host immunity and tumor metabolic activity, respectively. We investigated NLR and maximum SUV (SUVmax) as prognostic markers in metastatic pancreatic cancer (MPC) patients who receive palliative chemotherapy.We reviewed 396 MPC patients receiving palliative chemotherapy. NLR was obtained before and after the first cycle of chemotherapy. In 118 patients with PET prior to chemotherapy, SUVmax was collected. Cut-off values were determined by ROC curve.In multivariate analysis of all patients, NLR and change in NLR after the first cycle of chemotherapy (ΔNLR) were independent prognostic factors for overall survival (OS). We scored the risk considering NLR and ΔNLR and identified 4 risk groups with different prognosis (risk score 0 vs 1 vs 2 vs 3: OS 9.7 vs 7.9 vs 5.7 vs 2.6 months, HR 1 vs 1.329 vs 2.137 vs 7.915, respectively; P<0.001). In PET cohort, NLR and SUVmax were independently prognostic for OS. Prognostication model using both NLR and SUVmax could define 4 risk groups with different OS (risk score 0 vs 1 vs 2 vs 3: OS 11.8 vs 9.8 vs 7.2 vs 4.6 months, HR 1 vs 1.536 vs 2.958 vs 5.336, respectively; P<0.001).NLR and SUVmax as simple parameters of host immunity and metabolic activity of tumor cell, respectively, are independent prognostic factors for OS in MPC patients undergoing palliative chemotherapy.http://europepmc.org/articles/PMC4699704?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Younak Choi Do-Youn Oh Hyunkyung Park Tae-Yong Kim Kyung-Hun Lee Sae-Won Han Seock-Ah Im Tae-You Kim Yung-Jue Bang |
spellingShingle |
Younak Choi Do-Youn Oh Hyunkyung Park Tae-Yong Kim Kyung-Hun Lee Sae-Won Han Seock-Ah Im Tae-You Kim Yung-Jue Bang More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. PLoS ONE |
author_facet |
Younak Choi Do-Youn Oh Hyunkyung Park Tae-Yong Kim Kyung-Hun Lee Sae-Won Han Seock-Ah Im Tae-You Kim Yung-Jue Bang |
author_sort |
Younak Choi |
title |
More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. |
title_short |
More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. |
title_full |
More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. |
title_fullStr |
More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. |
title_full_unstemmed |
More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. |
title_sort |
more accurate prediction of metastatic pancreatic cancer patients' survival with prognostic model using both host immunity and tumor metabolic activity. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Neutrophil to lymphocyte ratio (NLR) and standard uptake value (SUV) by 18F-FDG PET represent host immunity and tumor metabolic activity, respectively. We investigated NLR and maximum SUV (SUVmax) as prognostic markers in metastatic pancreatic cancer (MPC) patients who receive palliative chemotherapy.We reviewed 396 MPC patients receiving palliative chemotherapy. NLR was obtained before and after the first cycle of chemotherapy. In 118 patients with PET prior to chemotherapy, SUVmax was collected. Cut-off values were determined by ROC curve.In multivariate analysis of all patients, NLR and change in NLR after the first cycle of chemotherapy (ΔNLR) were independent prognostic factors for overall survival (OS). We scored the risk considering NLR and ΔNLR and identified 4 risk groups with different prognosis (risk score 0 vs 1 vs 2 vs 3: OS 9.7 vs 7.9 vs 5.7 vs 2.6 months, HR 1 vs 1.329 vs 2.137 vs 7.915, respectively; P<0.001). In PET cohort, NLR and SUVmax were independently prognostic for OS. Prognostication model using both NLR and SUVmax could define 4 risk groups with different OS (risk score 0 vs 1 vs 2 vs 3: OS 11.8 vs 9.8 vs 7.2 vs 4.6 months, HR 1 vs 1.536 vs 2.958 vs 5.336, respectively; P<0.001).NLR and SUVmax as simple parameters of host immunity and metabolic activity of tumor cell, respectively, are independent prognostic factors for OS in MPC patients undergoing palliative chemotherapy. |
url |
http://europepmc.org/articles/PMC4699704?pdf=render |
work_keys_str_mv |
AT younakchoi moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT doyounoh moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT hyunkyungpark moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT taeyongkim moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT kyunghunlee moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT saewonhan moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT seockahim moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT taeyoukim moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity AT yungjuebang moreaccuratepredictionofmetastaticpancreaticcancerpatientssurvivalwithprognosticmodelusingbothhostimmunityandtumormetabolicactivity |
_version_ |
1724824962917728256 |